Breastfeeding News and Research RSS Feed - Breastfeeding News and Research

Many women choose to breastfeed their babies due to the significant health benefits provided over infant formula for both baby and mother.

Breast milk contains all the nutrients a baby requires for the first six months of life. Following this period, solid foods can gradually be introduced. The World Health Organization recommends feeding babies exclusively on breast milk for the first six months of life and then continuing breastfeeding once the infant has started to eat solid food, until up to two years of age.

Antibodies present in the breast milk boost the baby’s immune system and decrease the likelihood of diarrhoea, vomiting, or chest and ear infections developing. Breast feeding is also thought to decrease the risk of obesity later in life and therefore reduces the likelihood of conditions such as type 2 diabetes developing. Breast milk is also easier to digest than commercial formula.

For the mother, breastfeeding lowers the risk for breast and ovarian cancer as well as expending up to 500 calories a day, saving money, and helping to build a strong bond with the baby.

Any amount of breastfeeding has positive effects and the longer a child is breastfed for, the longer the health benefits will last for both baby and mother.
New collection of papers adds to mounting evidence of gut microbiome’s influential role in health

New collection of papers adds to mounting evidence of gut microbiome’s influential role in health

A newly released collection of papers, the result of the Gut in Focus Symposium Nobel Forum held earlier this year, is adding to the mounting evidence of the influential role the gut microbiome plays in health. [More]
Study: Osteopathic manipulative therapy decreases low back pain by over 70% in postpartum women

Study: Osteopathic manipulative therapy decreases low back pain by over 70% in postpartum women

German researchers found osteopathic manipulative therapy (OMTh) decreased postpartum low back pain by over 70 percent in women who had given birth at least three months before beginning treatment, according to a new study published in July issue of the Journal of the American Osteopathic Association. [More]
Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Health Canada is informing Canadians that eight unauthorized health products (listed in the table below) were seized from Better Bodies Supplements, 118 Main Street North, in Airdrie, Alta. [More]
Vitamin K-deficient bleeding increasingly common in newborns

Vitamin K-deficient bleeding increasingly common in newborns

Vitamin K, which has been administered to newborns as an injection since it was first recommended by the American Academy of Pediatrics in 1961, is vital for blood to clot normally. Despite it being given as standard medical practice since then, vitamin K-deficient bleeding (VKDB) is being seen more often in newborns than it has in decades. [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
Breastfeeding Medicine editorial examines risks associated with Internet-purchased breast milk

Breastfeeding Medicine editorial examines risks associated with Internet-purchased breast milk

The practice of breast milk sharing among mothers has evolved into an Internet-based marketplace in which this valuable commodity is being bought and sold not only to feed babies, but as a "natural superfood" for body builders and athletes. [More]
Orange sweet potato reduces prevalence and duration of diarrhea in children

Orange sweet potato reduces prevalence and duration of diarrhea in children

A new study has found that orange sweet potato (OSP) reduced both the prevalence and duration of diarrhea in young children in Mozambique. [More]
Early support important to help mom breastfeed successfully

Early support important to help mom breastfeed successfully

Most women understand the benefits of breastfeeding their infants, but there are physical and emotional roadblocks that can make it a challenge for moms. During the first weeks of a baby's life it is vital for mom to be able to focus on caring for herself and nursing her infant. [More]
WHO's updated essential medicines list includes progesterone contraceptive vaginal ring

WHO's updated essential medicines list includes progesterone contraceptive vaginal ring

The World Health Organization released its 2015 updated essential medicines list and for the first time included the progesterone contraceptive vaginal ring (CVR), a contraceptive safe and effective for lactating women in the postpartum period. [More]
Protective antibody response could be effective in preventing mother-to-child HIV transmission

Protective antibody response could be effective in preventing mother-to-child HIV transmission

How most babies are protected from acquiring HIV from their infected mothers has been a matter of scientific controversy. [More]
Maternal obesity increases health risks for mothers and their babies

Maternal obesity increases health risks for mothers and their babies

Women with obesity have a range of increased health risks in pregnancy, both for them and their babies, compared with those in the healthy weight category, according to a new systematic review of research by academics at the School of Nursing and Midwifery, Trinity College Dublin, the University of Gothenberg, and City University London. [More]
ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer. [More]
Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union. [More]
Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures. [More]
Group Health Research Institute conducts first randomized trial to tackle vaccine hesitancy

Group Health Research Institute conducts first randomized trial to tackle vaccine hesitancy

Group Health Research Institute conducted the first randomized trial to test an intervention aimed at improving hesitancy about early childhood vaccines by working directly with doctors. Vax Northwest, a Washington state public-private partnership, developed the intervention. [More]
Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9. [More]
Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types. [More]
Breastfeeding duration and intelligence: an interview with Dr Bernardo Lessa Horta

Breastfeeding duration and intelligence: an interview with Dr Bernardo Lessa Horta

Our research shows a benefit of breastfeeding on performance in IQ tests that was similar to the benefit reported in previous tests among children and adolescents, suggesting that the benefits of breastfeeding are still observed in adulthood... [More]
Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015. [More]
STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy. [More]
Advertisement
Advertisement